All In Biotech

Drug Trial Radar · NCT01449370

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease

Last checked: Nov 19, 2026Latest source record: Mar 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

125

Actual

Start

Oct 2011

Primary completion

Jul 2015

Study completion Jan 2016

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Oct 10, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.

Conditions

  • Metastatic Solid Tumors

Interventions

  • TAK-117Drug

    oral administration of TAK-117, daily and intermittent schedules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of TAK-117Time frame: Baseline up to Cycle 1 Day 21
  2. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Death, Adverse Events (AEs) Leading to Discontinuation of Study Drug, and DLTs in Cycle 1Time frame: Baseline up to Cycle 27 Day 45
  3. Number of Participants With Highest Level of TEAEs SeverityTime frame: Baseline up to Cycle 27 Day 45
  4. Number of Participants With Clinically Meaningful Changes in Laboratory ValuesTime frame: Baseline up to Cycle 27 Day 45
  5. Number of Participants With Clinically Meaningful Changes in Vital SignsTime frame: Baseline up to Cycle 27 day 45
  6. Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)Time frame: Baseline up to Cycle 27 Day 45

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Dallas, Texas

  • Site not named

    Barcelona, Spain

  • Site not named

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.